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Neurodegenerative Diseases: 
Potential Effect of Glutathione
Aoula Moustapha
Abstract
Neurodegenerative diseases are characterized by the progressive deterioration 
of neuronal function in the central or peripheral nervous system and ultimately 
the death of nerve cells. There is a big evidence that oxidative stress is an essential 
mediator implicated in neurodegenerative processes and may be a key event trig-
gering various forms of cell death. Here, we review the hypothesis that neuronal 
loss resulted from oxidative stress may be initiated by a drastic decrease in the 
antioxidant molecule glutathione (GSH). The impairment of physiological gluta-
thione's levels and the alterations in the activities of its related enzymes in neuronal 
cells are increasingly suggested to be implicated in the initiation and progression of 
neurodegenerative diseases. GSH plays a vital role in cellular redox homeostasis in 
the nervous system and protects neurons against a variety of oxidative insults. GSH 
depletion can enhance oxidative stress and may increase protein aggregation lead-
ing to initiate cell death in distinct neuronal populations. Evidence demonstrates a 
grand impact of oxidative stress and loss neuronal GSH in Parkinson’s disease and 
Alzheimer’s disease.
Keywords: mitochondria, oxidative stress, protein aggregation, cysteine, redox 
signaling
1. Introduction
During the past thirty to forty years, and along with the global rise in life 
expectancy, neurodegenerative diseases of the brain that affect the elderly in 
particular have become a burden on society more and more. The European Union 
(EU) Joint Programme-Neurodegenerative Disease Research (JPND) states that 
by the year 2030, a quarter (25%) of the European population will be over age 65, 
a significant increase over the current 16%. [1]. Thus, the scientists place a special 
focus on age-related neurodegenerative diseases (ADD) research. These ADD 
such as Alzheimer's Disease (AD) and Parkinson's Disease (PD) have become more 
common and have drawn a lot of attention due to their irreversibility and lack of 
effective treatment [2]. Neurodegenerative diseases (DD) are known by gradual 
damage in neural cells and neuronal loss, which conduct to impaired motor or 
cognitive function. Largely, treatment is accomplished by reducing symptoms 
more than researching disease physiology and heading to the mechanisms that limit 
disease progression [3]. The mediating pathogeneses in neurodegenerative diseases 
are still not fully illustrated; however, great evidence demonstrates that reactive 
oxygen species (ROS) could be a key event as an elevated level of oxidative stress 
(OS) has been observed in the brain of DD patients [4]. In recent decades, a broad 
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range of studies has shown that the development of age-dependent neurodegen-
eration is due to a decrease in the antioxidant efficacy and an increase in oxida-
tive damage. Cumulative ROS can cause damage to biomolecules such as lipids, 
proteins and DNA, in addition to mitochondrial dysfunction [5]. The increasing 
prevalence of DD and their profound hindrance to the quality of patient’s life make 
it necessitous to come up with effective and novel treatment approaches, such as 
enhancing glutathione level in neurons. Glutathione (GSH) is a major antioxidant 
whose levels are found to decrease in aging as well as in DD. Scientists are currently 
heading to fully understand the role of GSH depletion in these diseases in addition 
to exploit that to develop GSH-based treatment. Glutathione is an essential cellular 
component, as it is primarily responsible for protecting and defending cells against 
any risk caused by exposure to ROS, and this role is evident, especially in the brain. 
Thus, GSH homeostasis disturbance and GSH-dependent enzymes inactivation lead 
to the breakdown of the main protective barrier against ROS and as a result, the cell 
becomes more vulnerable to the damage caused by OS [6].
In this chapter, we highlighted the OS in terms of its stimulating effect on the 
initiation and development of common ADD. We also demonstrated the great impor-
tance of glutathione in preserving nerve cells from the damage that OS may cause and 
the intracellular changes resulting from its depletion that may exacerbate the disease.
2. Oxidative stress and neurodegenerative disorders
2.1 Reactive oxygen species in brain
Although the human brain makes up only 2% of the body’s weight, its oxygen 
requirements are estimated at 20% of the body’s oxygen consumption. The brain 
is classified among the most generating organs for the reactive oxygen species 
(ROS), where 4% of the oxygen consumed by the mitochondria is converted into 
super oxide superoxide ion (O2•–), which possesses exceptionally high reactivity, 
particularly as a powerful oxidizing agent and an initiator of radical reactions. 
There are three radical reactions mainly initiated by superoxide “Figure 1” (i) 
under the influence of superoxide dismutase (SOD), the superoxide is converted 
into hydrogen peroxide (H2O2), which is subsequently converted to water and 
molecular oxygen by GSH peroxidase (GPx) or catalase. (ii) H2O2 can also react 
with iron, found in high concentration in brain, via the Fenton reaction to form 
hydroxyl radicals (OH.), which trigger lipid peroxidation. (iii) Superoxide also 
interacts with nitric oxide, which is formed in large quantities in the brain by an 
enzyme neuronal NO synthase (nNOS). This reaction is a million times faster than 
Fenton and produces the toxic oxidant peroxynitrite (ONOO−), which can spread 
10,000 times farther than hydroxyl radicals. Harmful effects of ONOO− are varied 
including oxidation of macromolecules (DNA, proteins, lipids), nitration of amino 
acids and inactivating mitochondrial enzymes leading to mitochondrial dysfunc-
tion. It is now possible to detect specific markers that are byproducts of the oxidized 
endogenous macromolecules. For instance, 4-hydroxyl 2, 3-nenonal (HNE) is a 
marker of unsaturated lipid oxidation, which it has many cellular toxic effects such 
as irreversible formation of protein adduct and inhibition of GPx activity, and thus 
contributes in elevated levels of H2O2 [7].
2.2 Underlying role of oxidative stress in neurodegeneration
A large body of evidence demonstrates a particular susceptibility of neurons 
to ROS because of their distinctive characters: High energy demands, high oxygen 
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consumption, high levels of iron, polyunsaturated fatty acids and, in particular, 
low anti-oxidative protection [8]. The defense enzymatic system in neuronal cells 
is weak where the SOD, catalase, and GPx activities are low compared to other 
organs. In addition, glutathione, an essential anti-oxidant component, is present in 
the brain at low concentrations. These findings suggest the involvement of ROS in 
neurodegenerative diseases [4, 8, 9].
The OS was one of the important axes of research conducted to understand 
the pathogenesis of neurodegeneration. A number of research confirmed a strong 
involvement of oxidative stress in the pathophysiology of neurodegenerative 
diseases through a variety of mechanisms including induction of oxidation of 
macromolecules such as nucleic acids, proteins, lipids, mitochondrial dysfunction, 
glial cell activation, amyloid β deposition, apoptosis, and proteasome dysfunction 
[3, 5, 10, 11]. A systemic review showed that these mechanisms of neurodegenera-
tion are involved in many harmful cellular pathways. It has been observed that the 
interference in these pathways in complex ways has the greatest impact on disease 
development [12], apoptosis, cytokine production and inflammatory responses, and 
proteasome dysfunction. Currently, there is an increasing focus on the effects of OS 
on the pathogenesis of neurodegenerative diseases (DD) and the effectiveness of 
antioxidants as a promising treatment for DD.
3. Glutathione homeostasis and neurodegenerative diseases
Glutathione (GSH) is a thiol-containing tripeptide of major significance in 
normal brain function. GSH is formed from glutamate, cysteine, and glycine. 
The γ-carboxyl group of glutamate links the N-terminal glutamate and cysteine 
residues, unusual peptide bond. This specific peptide bond protects GSH against 
cleavage by intracellular peptidases preventing its hydrolysis and making GSH 
moderately stable in the cell. In addition, the presence of the C-terminal glycine 
residue in GSH structure prevents its cleavage by intracellular γ-glutamyl cyclo-
transferase. The cysteine residue is an effective functional component of GSH as 
Figure 1. 
Generation of ROS and Implication of glutathione in ROS/RNS elimination. As a result of mitochondrial 
respiration, the superoxide (O2-) is generated from O2. This latter can be converted into hydrogen peroxide 
(H2O2) by superoxide dismutase (SOD). A number of other ROS such as hydroxyl radicals (·OH) and 
hydroxyl anions (OH-) can be produced from H2O2. Hydroxyl radical and nitric oxide or peroxynitrite may 
interact directly with GSH forming GSSG. GSH serves as an electron donor for the reduction of H2O2 or other 
peroxides, catalyzed by GPx, and as result, it is converted to GSSG.
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it provides thiol group, a principle responsible for the GSH activity. Moreover, 
cysteine residues form the intermolecular dipeptide bond in the oxidized form of 
GSH. Glutathione disulfide (GSSG), the major oxidized form, involves two residues 
of GSH that have been oxidized and connected by an intermolecular disulfide bond.
3.1 GSH content and synthesis
GSH is present in brain at elevated concentration (2–3 mM) compared to blood 
(15 μM) and cerebrospinal fluid (CSF) (5 μM) [13, 14]. Some evidence has been 
demonstrated that GSH is very poorly transported intact across the blood-brain bar-
rier (BBB). However, it is probable that the blood is not the major source of cerebral 
GSH. This indicates that there is an avid brain system assures its synthesis in situ [15].
Generally, for maintaining GSH homeostasis in brain, there are at least two pos-
sible mechanisms: (i) glutathione constituents (cysteine moieties) may be recovered 
and recycled during the turnover of GSH in the brain, and (ii) precursors for brain 
glutathione synthesis (cysteine, cysteine-containing molecules) might be transported 
across the blood-brain barrier [13]. Cysteine is the rate-limiting substrate for neuro-
nal GSH synthesis [15, 16]. In contrast, the availability of glutamine or glycine does 
not limit neuronal glutathione synthesis [13]. Therefore, cysteine alone is the crucial 
amino acid for neuronal GSH synthesis [17]. The neuronal uptake of cysteine is medi-
ated by sodium-dependent systems, mainly the excitatory amino acid transporters 
(EAATs) [18]. EAATs have a significant function in removing extracellular glutamate 
in the CNS [19]. EAAT can transport not only excitatory amino acids, for example, 
glutamate and aspartate, but also cysteine, in particular, EAAT3, also known as 
EAAC1 that can transport cysteine at a rate comparable to that of glutamate [19].
Cystine, an oxidized form of two cysteines with a disulfide [20] linkage, is other 
source of free cysteine and employed as a substrate for GSH synthesis in some types 
of brain cells. Cystine moieties are transported into brain as (i) γ-glutamylcystine 
or as (ii) cystinylbisglycine which are possible origins of GSH in brain [21]. Cystine 
is especially important in maintaining glutathione levels in astrocytes [22], while it 
has no significance in the synthesis of neuronal GSH due to the inability of neurons 
to uptake it. Therefore, Content of cysteine or cysteine precursors determines the 
glutathione level in neurons since neurons are not able to use the cystine but rather 
rely on the availability of cysteine for their glutathione synthesis [20]. In addition 
to cysteine, neurons can utilize the cysteine donors such as CysGly, γGluCys, and 
N-acetylcystein (NAC) as precursors for glutathione. The presence of methionine 
does not increase neuronal glutathione levels [23]. Methionine is the main precursor 
of cysteine in liver, which supplies 50% of the cysteine needed for GSH synthesis. 
However, its role in producing cysteine in the brain is negligible and thus the neu-
ronal GSH synthesis is not related to supply of methionine [16]. Among the exog-
enous precursors of glutathione, the dipeptide CysGly may be the most important. 
CysGly is efficiently utilized by neurons in micromolar concentrations [24].
Astrocytes store and synthesize high levels of GSH compared to neurons  
[13, 25, 26]. This is explained by the inability of neurons to directly uptake GSH. As 
well as, neurons utilize cysteine, not cystine, for GSH synthesis, whereas astrocytes 
utilize both [27, 28]. According to the above, neurons rely mainly on astrocytes to 
supply the necessary cysteine to neuronal GSH synthesis. GSH, released by astro-
cytes, undergoes a cleavage process by γ-glutamyl transpeptidase (γGT) [29] pro-
ducing a γ-glutamyl moiety and a dipeptide CysGly which is an essential precursor 
of neuronal glutathione. The dipeptide CysGly could be uptake into neurons via a 
peptide transporter as has been described for astrocytes [30]. The dipeptide CysGly 
is hydrolyzed, upon entry into the neuron, by a neuronal ectopeptidase, provid-
ing cysteine and glycine [20] which subsequently are taken up as precursors for 
5Neurodegenerative Diseases: Potential Effect of Glutathione
DOI: http://dx.doi.org/10.5772/intechopen.92240
glutathione synthesis. Glutathione is synthesized by two successive enzymatic steps 
dependant on ATP [13, 20]. the first step include γ-glutamylcysteine synthetase 
(GCL) which mediates the first reaction between glutamate and cysteine to form 
a dipeptide, γ-glutamylcysteine (γGluCys) which in turn combines with glycine to 
produce GSH. When a sufficient amount of glutathione is synthesized, a feedback 
occurs where GCL is inhibited [31]. Conversely, GSH depletion causes in the short 
term an increase in GCL activity and consequently an increase in GSH synthesis.
3.2 GSH activity against OS
The adult mammalian brain has a great demand for energy, and it almost relies 
entirely on metabolism of glucose. Most of the glucose is completely oxidized to car-
bon dioxide to meet energy requirements. This very high ability to oxidize glucose 
indicates that the brain may produce ROS at a remarkable rate. This increase in ROS 
production combines with low levels of defense mechanisms such as catalase and a 
high lipid content in brain. All of these indicate that the brain may be particularly 
vulnerable to OS.
GSH plays a leading role in reducing high levels of ROS and minimizing oxidative 
damage in brain (Figure 1). This importance has been established by several studies 
demonstrating that OS was aggravated by the GSH depletion, while increased intra-
cellular GSH improved this damage [32]. GSH is a great component that provides 
protection against OS in brain by a direct interact with superoxide [33], NO [34], 
hydroxyl radical [35], and ONOO− [36]. The GSH capacity to scavenge superoxide 
is higher than NAC or cysteine [37]. Moreover, GSH is a principle hydroxyl radical 
scavenger because of unavailability of enzymatic defense against these radicals. 
On the other hand, GSH participates in enzyme-catalyzed redox cycling. The most 
important enzyme in glutathione redox reaction is glutathione peroxidase (GPx) 
due to its leading role in the reduction of toxic H2O2 (or lipid peroxide, ROOH) to 
H2O (or ROH). GSH serves as an electron donor for the reduction of H2O2 or other 
peroxides, catalyzed by GPx, and as result, it is converted to GSSG [21]. The glu-
tathione redox cycle, is completed by glutathione reductase (GR). This GSH redox 
cycle takes place in the cytosol and mitochondria, whereas GSH is compartmental-
ized in mitochondria [38], the major intracellular source of ROS [39], after its syn-
thesis in cytosol. Catalase also reduces H2O2 to H2O but it is unable to detoxify lipid 
peroxides and is not exist in mitochondria of most tissues. For these reasons, GPx is 
especially significant in protecting of mitochondria against H2O2,that are constantly 
generated during cell respiration [40, 41]. Mitochondria contain 5–15% of total 
cellular GSH [42]. The maintenance of this mitochondrial GSH pool occurs through 
the action of a high-affinity GSH uptake system [43] which is a main determinant 
of neuronal susceptibility to OS [44]. Depletion of this pool in brain mitochondria 
makes them more vulnerable to toxic effects of H2O2 leading to irreversible damages 
[45] and death. If mitochondria are not protected against OS insult, the organelles 
become irreversibly damaged through a process culminating with induction of a 
mitochondrial permeability transition (mPT) which is associated with the collapse 
of mitochondrial membrane (ΔΨ) and colloid osmotic swelling of the matrix [46]. 
As well, GSH detoxifies many agents that can induce the mPT in brain mitochondria 
including 4-hydroxyhexenal (a lipid peroxide) [39]. These findings indicate that 
GSH has a high significance in maintaining mitochondrial integrity in brain and 
other organs. Moreover, GSH is a substrate for glutathione S-transferase (GST) that 
catalyze GSH-dependent reduction of lipid peroxides. In addition to the above, there 
is a potential synergistic relationship between reduced glutathione and vitamin E, 
another line of defense. This vitamin is well recognized as antioxidant incorporat-
ing into cellular membranes to inhibit lipid peroxidation [47]. Lipids are protected 
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against ROS by α-tocopherol (vitamin E), which quenches ROS and by that, con-
verts to α-tocopheroxyl radical. This latter can re-reduced non-enzymatically to 
α-tocopherol by GSH [48]. This reaction and those that are catalyzed by GPx and 
GST possess peroxidase activity and form a protective barrier of the brain against 
damaging effects of H2O2 on polyunsaturated fatty acids in biomembranes (lipid 
peroxidation) [49].
Many of studies have been demonstrated the specific toxicity of Hydrogen 
peroxide to brain [42, 43, 50]. This peroxide induces apoptosis in neuronal cells which 
are particularly sensitive to its toxic effects [51]. Nevertheless, neurons can detoxify 
H2O2, but apparently this capacity is more greater in astrocytes for which they play a 
putative role in the modulation of the neurotoxic effects of H2O2 [45, 46, 52].  
The neuronal defense system against H2O2 is mainly based on glutathione redox cycle. 
This role of GSH is clearly illustrated by a rapid oxidation of GSH when H2O2 is appli-
cated to neurons [53]. Intracellular GSH depletion enforces mitochondrial damage 
and causes cell death. Apoptosis has been hypothesized to be mediated through the 
induction of free radicals via oxidative pathways. Thus, a direct cause/effect relation-
ship between GSH depletion and apoptosis was evidenced in neuronal cell [54]. In 
addition, GSH depletion is an early hallmark in the progression of cell death [55].
3.3 Implication of glutathione in neurodegenerative disorders
It has been previously emphasized that the breakdown of the balance between 
ROS and antioxidant defense systems is the main manipulator triggering the 
initiation or progression of a number of common neurodegenerative diseases 
such as Parkinson’s (PD) and Alzheimer’s (AD) diseases. Each of these diseases 
depends on a number of factors including mainly OS. However, the causative link 
between OS and neurodegeneration is not in the scope of this part as it focuses on 
the dysregulation of the GSH-based antioxidant network in the context of common 
neurodegenerative diseases: Parkinson’s disease, Alzheimer’s disease [6].
3.3.1 Parkinson’s disease (PD)
The primary pathologic hallmarks of PD are loss of dopaminergic neurons 
located in an area of the brain called the substantia nigra pars compacta, and the 
presence of Lewy bodies, intracellular aggregates of misfolded α-synuclein, in 
dopaminergic neurons and likely contribute to the death of these neurons. Neurons 
in the substantia nigra pars compacta produce dopamine, a neurotransmitter 
(chemical messenger) that transmits signals from the substantia nigra to other 
parts of the brain. These other parts of the brain are collectively called the “basal 
ganglia”. Communication among neurons of the substantia nigra pars compacta 
and the basal ganglia produce smooth, purposeful movement. When the neurons in 
the substantia nigra are damaged in large numbers, the loss of dopamine prevents 
normal function in basal ganglia and causes the motor symptoms of PD: tremor, 
rigidity, impaired balance, and loss of spontaneous movement [56].
Dopaminergic SN cells are usually pigmented with black neuromelanin, pro-
duced from of the autoxidation [57] or enzyme-mediated oxidation [58] of the 
cytoplasmic dopamine (DA) to DA-o-quinone, which then Polymerizes. Usually, 
this process is accompanied with production of H2O2 rendering dopaminergic SN 
cells are particularly sensitive to OS probably. It has been reported that dopami-
nergic SN neurons having high basal levels of DA oxidation, heavily pigmented, is 
particularly vulnerable to degeneration in PD [59].
A massive loss of nigral GSH is the most notable distinctive changes that occur 
in the earliest stage [60] in the parkinsonian SN. This GSH loss is uncorrelated to 
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altered activities of biosynthetic enzyme and not accompanied by an increase in 
GSSG levels [61]. It has been indicated that the drastic drop in GSH is attributed to 
raise in activity of γ-GT, causing an increased removal of both GSH and GSSG from 
cells [61]. It is interesting that GSH depletion is characteristic to the parkinsonian SA 
and is not observed in other neurodegenerative disorders of the basal ganglia [62].
GSH depletion cause indirectly formation of endotoxins in the cytoplasm 
of pigmented SN cells that contribute to the degeneration of these neurons in 
PD “Figure 2.” As previously mentioned the activity of γ-GT is up-regulated 
significantly in the parkinsonian SN [61]. This enzyme is involved in transloca-
tion of free cysteine into dopaminergic SN neurons and expulsion of GSH out of 
these cells. Thus, the profound loss of nigral GSH, main storage form of cysteine, 
makes the free cysteine, which is increasingly transported into the cell, more 
likely to bind to oxidizing dopamine and formation DHBTs (dihydrobenzothi-
azines) by a series of consecutive reactions [63]. These compounds are lethal 
and evoke profound neurobehavioral responses, especially DHBT-1 which cause 
irreversible inhibition of mitochondrial complex I [64].
The presence of Lewy bodies, aggregated misfolded α-synuclein, in SN is also 
characteristic hallmarks to PD which mainly participate in neurodegeneration [65]. 
The plurality of intracellular proteins is degraded by the ubiquitin (Ub)–protea-
some pathway (UPP). In this pathway, the protein Ub, belongs to a family of heat 
shock proteins (HSPs), is covalently bound by thiol groups to misfolded or damaged 
proteins and contributes in their breakdown by transferring them to the protease 
26S complex. There are three enzymes contributing to UPP: E1 (Ub-activating 
enzyme) and E2s (Ub-carrier) prepare Ub for conjugation, but the main enzyme in 
the process is the E3 (Ub-protein ligase) which transfers the activated ubiquitin to 
the protein substrate to be degraded [66]. Any defect in the components of UPP or 
a lack of their activity result in accumulation of α-synuclein protein and subsequent 
aggregation leading in turn to the formation of Lewy bodies. The depletion in GSH 
in dopaminergic SN neurons leads to decreased E1 activity and subsequent UPP 
Figure 2. 
Consequences of GSH depletion in SN dopaminergic neuronal cells in PD. Drastic loss of GSH is associated 
with protein aggregation which form Lewy bodies, mitochondrial dysfunction resulted from inhibition of 
complex I activity and oxidative damage including protein oxidation and the deleterious effects of the lipid 
peroxidation by-product 4HNE.
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disturbance [67]. This finding indicates that GSH protects the active sites of these 
enzymes from being oxidized during oxidative stress, and thus keeps them per-
forming in the Ub-proteasome pathway.
Additionally, the early GSH loss in parkinsonian SN accompanied by increased OS 
leads to raise in oxidized proteins. In the early stage of PD, HSP proteins are expressed 
at high levels to prevent the deleterious effects resulting from accumulation and 
aggregation of damaged proteins in dopaminergic neurons. As the disease progresses, 
these defenses become unable to control the build-up of protein aggregates [68].
OS also target the mitochondria and interfere with all of their functions. 
Mitochondrial disorders occupy a crucial place in the mechanisms that mediate 
neurodegeneration associating with the pathology of PD [69]. Since glutathione 
is the main component in detoxification of hydroperoxides in mitochondria, its 
depletion in the brain is believed to promote mitochondrial insult most likely via 
increased ROS. The mitochondria are known by their vulnerability to OS that 
might interfere with all of their functions. By serving as the main component in 
detoxification of hydroperoxides in mitochondria, GSH may reduce the oxidative 
insults that affect mitochondria. GSH depletion in the brain therefore is believed to 
promote mitochondrial insult most likely via increased ROS [70].
In synaptic mitochondria, the major role in control over oxidative phosphory-
lation is attributed to complex I that at 25% inhibition, energy metabolism is 
disturbed and ATP synthesis is drastically affected. To manifest similar effects 
[71], complex III and IV inhibition up to 80% is necessitated. The reduced 
complex I activity in the SN is known as a considerable biochemical character-
istic in Parkinsonian brain [72]. Evidence suggest that Early depletions in nigral 
GSH levels may be directly lead to mitochondrial complex I activity inhibition 
and subsequent mitochondrial dysfunction which ultimately induces dopami-
nergic cell death related to PD. The complex I is the most severely influenced 
mitochondrial enzymes during OS [73]. It is believed that OS, due to decreased 
GSH availability in the brain, is the major responsible of mitochondrial complex 
I activity inhibition. This susceptibility of complex I to OS might be explicated 
by the oxidation of thiol (SH) groups of protein and the existence of accessible 
oxidation sensitive iron-sulfur centers in this complex [74].
It is recognized that GSH controls the activity of thiol-dependent proteins by 
keeping the SH groups of protein in a reduced state and preventing them from 
oxidation [75]. GSH conjugates with oxidized thiol groups to form protein-SS-G 
and subsequently can be re-reduced to protein and GSH by GR, thioredoxin or 
protein disulfide isomerase. In addition, GSH, present in dopaminergic cells, can 
bind to quinones resulted from dopamine oxidation preventing their reaction with 
SH groups in protein [76].
Lastly, during oxidative insult, aldehydes are formed as a byproduct; the most 
common of these types is 4HNE. This latter is able to incorporating into the mem-
branes causing changes in their fluidity [77]. In addition, 4HNE can form adducts 
with important proteins like Na/K ATPas making them inactive. GSH may help 
reduce the levels of 4HNE by conjugating it via GST. In the PD brains, the loss in 
GSH in the SN results in high levels of 4HNE adducts [78].
3.3.2 Alzheimer’s disease (AD)
AD, the most common age-related neurodegenerative disease, is known by pro-
gressive dementia affecting older populations. This disease is pathologically charac-
terized by depositions of amyloid β (Aβ) plaques and neurofibrillary tangles (NFTs) 
[14]. The presence of amyloid plaques, which are mainly composed of Aβ peptide, 
in the extracellular space of AD brain is a main hallmark of disease. The excess of 
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Aβ levels, especially Aβ 42, the most neurotoxic peptide, causes the emergence of 
familial forms of Alzheimer's disease. This increase in Aβ 42 leads to the formation 
of soluble oligomers, causing permanent changes in synaptic function. In parallel, 
Aβ 42 is aggregated forming mostly β-sheet rich fibrils that enhance local inflam-
matory responses (microgliosis and astrocytosis). Synaptic spine loss and neurotic 
dystrophy are also observed. Over time, these events result in a biochemical changes 
including oxidative stress, altered ionic (e.g.; calcium) homeostasis [79]. Amyloid 
plaques are the determining factor in triggering a signaling pathway leading to AD 
progression. Recent evidence suggests that Aβ plaques induce neuronal apoptosis 
in the brain and in primary neuronal cultures, and this Aβ-induced neuronal 
death may be responsible in part for the cognitive decline found in AD patients. In 
addition, aggregated Amyloid-β activates the p38 mitogen activated protein kinase 
(MAPK) in cell leading to hyperphosphorylation of protein Tau and formation of 
neurofibrillary tangles (NFTs) inside neurons, making the microtubules unstable 
and causing the loss of neuron functionality [80].
Evidence demonstrates that Soluble Aβ oligomers are able to block the EAAC1-
mediated cysteine uptake leading to a GSH loss in cultured human neuronal cells 
[81]. This is supported by autopsy brain of AD patients, which exhibit aberrant 
EAAC1 accumulation in pyramidal neurons of the hippocampus [82] and decreased 
GSH/GSSG ratios with the progress of disease [83].
Based on the above, it is possible to emphasize the notion of EAAC1 dysfunction 
in Alzheimer’s disease.
Oxidative stress is considered a major pathogenic factor in AD. Since GSH 
depletion is of immense implication in oxidative stress, it is expected to have a role 
in the emergence and development of the disease. A recent clinical study using 
NMR spectroscopy showed that GSH level is depleted in AD patients as compared 
to healthy subjects [84]. This finding may have a profound clinical significance. 
In addition, the analysis of the blood samples of AD patients showed a decrease 
of GSH concentration in red blood cells compared to age- and gender-matched 
controls [85]. This is also observed in mild cognitive impairment (MCI) which is a 
preclinical stage of AD. MCI patients showed a decrease in GSH/GSSG ratios and 
GST activity in the hippocampus compared to healthy age-matched controls [86]. 
According to these results, it is suggested that disturbances in GSH metabolism 
precede the onset of AD. Genetic polymorphisms in the GPx-1 and GST genes were 
identified as positive risk factors for AD [87]. This can be the reason of decreases in 
GPx and GST activities in AD [88].
As was previously mentioned, ROS formation is induced by Aβ aggregating and 
cause a number of oxidative damages and metabolic insults including generation of 
HNE in hippocampal neurons, which could in turn mediate the toxicities of such 
insults [89]. Several studies have been shown an increase in lipid peroxidation in 
the brain of AD patients compared with age-matched controls [90]. As a result 
of lipid peroxidation, HNE, secondary bioactive aldehyde, is produced at a high 
levels in several brain regions of late-stage AD subjects [89]. The significant role 
of HNE in the progression of AD is supported by many findings. Accordingly, an 
increased level protein-bound HNE in brain of MCI patients was observed [91]. 
Many proteins were found to be significantly HNE-modified in AD such as ATP 
synthase, glutamine synthase, DRP-2, and MnSOD. These proteins have a great 
implication in the regulation of structural functions of brain cell in addition to a 
number of cellular functions including cellular signaling, energy metabolism and 
detoxification. Evidence showed that GSH could prevent oxidative damage induced 
by Aβ and HNE in cultured neuronal cells. This finding suggests that GSH depletion 
exacerbates oxidative insults stimulated by Aβ and HNE and therefore accelerates 
the development of the disease.
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4. Conclusion
GSH is an interesting subject studied intensively in the brain for the past several 
decades. The purpose of such research is not only to understanding the potential 
role of intracellular GSH in preventing DD progression but also to provide the 
mechanistic insights contributing to the cellular dysfunctions associated with these 
diseases. GSH depletion is a common feature of DD triggered by a wide variety 
of cause including disturbance in GSH homeostasis and modification of the GSH 
related enzymes. Multiple cellular problems attributed to dysregulation of GSH and 
GSH-dependent enzymes contributes to impairment in the function of mitochon-
dria, elevation in oxidative damage, disruption of intracellular signal transduction 
pathways, protein aggregation, and eventually cell death.
It is important to note that further research is necessary to determine more 
accurately the involvement of disruption of the network of glutathione-dependent 
reactions in the neurodegenerative events and find new ways to prevent or limit 
these events. As well to suggest more effective approaches therapy for DD patients.
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Acronyms and abbreviations
EU European union
JPND joint programme-neurodegenerative disease research
GSSG glutathione disulfide
GPx glutathione peroxidase
GST glutathione S-transferase
GS glutathione synthetase
GR glutathione reductase
PD Parkinson’s disease
AD Alzheimer’s Disease
DD neurodegenerative diseases
RNS reactive nitrogen species
ROS reactive oxygen species
GSH reduced glutathione
OS oxidative stress
4HNE 4-hydroxyl 2, 3-nenonal
EAAC1 excitatory amino acid transporter C1
EAAT excitatory amino acid transporter
GCS γ-glutamylcysteine synthetase
NFTs neurofibrillary tangles
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